Figure 2.
Validation of hIL-36γ binding and functional assays for compound triage. (A) Binding between Alexa-488 labeled hIL-36γ and hIL-36R/hIL-1RAcP ECD heterodimer was measured by FRET ratio (left panel, n = 3). Inhibition of interaction between labeled hIL-36γ and heterodimer was assessed by displacement using either unlabeled hIL-36γ (middle panel, n = 3) or hIL-36Ra (right panel, n = 2). (B) hIL-36γ function was measured by its ability to induce the secretion of IL-8 in human keratinocyte derived cell line HaCaT (left panel, n = 3). Ability to inhibit hIL-36γ function was assessed using hIL-36Ra (right panel, n = 3). (C) hIL-1β function was measured by its ability to induce the secretion of IL-8 in HaCaT cells, n = 3. (D) Human-to-mouse cross-species activity of hIL-36γ was measured by its ability to induce the secretion of CXCL1 from mouse NIH 3T3 cells, n = 2. (E) Specificity of cross-species activity of hIL-36γ was tested by functional inhibition using mouse (left panel, n = 2) and human (right panel, n = 2) IL-36Ra. All data represents an average ± S.E.M.